Suwanjutha S, Chantarojanasiri T
J Int Med Res. 1985;13(1):24-30. doi: 10.1177/030006058501300104.
The efficacy and safety of ketotifen in the treatment of recurrent bronchitis were studied in twenty Thai children with an average age of 5.3 years. Symptoms studied were cough, hypersecretion and wheezing and 4-point rating scores were assigned to each of the symptoms with regard to their frequency, severity and duration. Score per dose of the symptomatic agents used was also given. The symptoms and the use of symptomatic agents were recorded during a full year prior to ketotifen treatment and during a further full year study period. PEFR measurement was performed in the children above the age of 6 years at 2-weekly intervals under the supervision of the authors at the clinic. Assessment of efficacy was done by comparing monthly symptom scores and medication scores during the study period with the mean value of the previous year. Thirteen children received ketotifen for the whole year while seven children who were almost symptom-free after 4 months ketotifen treatment, were then only observed for a further 8 months. At the end of the study period, ketotifen treatment was rated very good and good in 85% of children, satisfactory in 10% and poor in 5%. Drowsiness was the only side-effect reported in a few cases but then only initially. There were no abnormalities in any laboratory parameters studied.
在20名平均年龄为5.3岁的泰国儿童中研究了酮替芬治疗复发性支气管炎的疗效和安全性。所研究的症状为咳嗽、分泌物过多和喘息，并根据症状的频率、严重程度和持续时间对每种症状进行4分制评分。还给出了所用对症药物每剂的评分。在酮替芬治疗前的一整年以及另外一整年的研究期间记录症状和对症药物的使用情况。在诊所作者的监督下，对6岁以上儿童每两周进行一次呼气峰流速（PEFR）测量。通过比较研究期间的每月症状评分和用药评分与前一年的平均值来评估疗效。13名儿童接受了一整年的酮替芬治疗，而7名儿童在接受酮替芬治疗4个月后几乎无症状，随后仅再观察8个月。在研究期结束时，85%的儿童酮替芬治疗评定为非常好和良好，10%为满意，5%为差。嗜睡是少数病例报告的唯一副作用，但仅在最初出现。所研究的任何实验室参数均无异常。
